Metabolism and pharmacokinetics of radium-223 in prostate cancer Journal Article


Authors: Yeku, O.; Slovin, S. F.
Article Title: Metabolism and pharmacokinetics of radium-223 in prostate cancer
Abstract: Introduction: Prostate cancer metastatic to bone is a cause of significant morbidity and mortality. Bone pain and other skeletal events negatively impact the quality of life in patients who might otherwise be functioning well. As such, there has been intense interest in the development of strategies and pharmaceuticals to address this problem.Areas covered: The authors reviewed the current literature for articles relevant to metastatic prostate cancer, clinical radiopharmaceuticals, castrate-resistant prostate cancer and development of Radium-223. The authors have referenced primary literature, clinical trials and relevant review articles that summarize the history, development and current utilization of radiopharmaceuticals for management of bone metastases from prostate cancer.Expert opinion: Radium-223 is the first radiopharmaceutical with an overall survival benefit approved for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastasis and no known visceral metastatic disease. The additional benefit of clinically significant improved overall survival should lead to exploration of whether this agent can be used earlier in the treatment algorithm or combined with chemotherapy or androgen deprivation therapy. An individualized approach needs to be tailored to each patient based on their overall symptoms, disease burden, hematologic profile and goals of care. © 2015 Informa UK, Ltd.
Keywords: cancer chemotherapy; overall survival; cisplatin; nonhuman; bone metastasis; cancer pain; docetaxel; prostate cancer; algorithm; radiopharmaceutical agent; visceral metastasis; drug metabolism; androgen deprivation therapy; castration resistant prostate cancer; bone metastases; clinical trial (topic); samarium 153; strontium 89; radionuclide therapy; alpharadin; radium-223; radium chloride ra 223; human; article; metastatic castrate-resistant prostate cancer
Journal Title: Expert Opinion on Drug Metabolism and Toxicology
Volume: 11
Issue: 5
ISSN: 1742-5255
Publisher: Informa Healthcare  
Date Published: 2015-05-01
Start Page: 843
End Page: 849
Language: English
DOI: 10.1517/17425255.2015.1021332
PROVIDER: scopus
PUBMED: 25740232
DOI/URL:
Notes: Export Date: 3 June 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Susan Slovin
    184 Slovin
  2. Oladapo Olumoroti Yeku
    11 Yeku